Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.

@article{Bergqvist1996LowmolecularweightH,
  title={Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.},
  author={David Bergqvist and G{\"o}ran Benoni and Ola Bj{\"o}rgell and Hans Fredin and Urban Hedlundh and S Nicolas and Paul E. Nilsson and G{\"o}ran Nylander},
  journal={The New England journal of medicine},
  year={1996},
  volume={335 10},
  pages={
          696-700
        }
}
BACKGROUND The risk of venous thromboembolism in patients undergoing total hip replacement is known to be high. However, the optimal duration of prophylaxis with anticoagulant agents after this procedure is unknown. We sought to determine whether one month of anticoagulant therapy with the low-molecular-weight heparin enoxaparin is more effective than enoxaparin therapy given only during the hospitalization for surgery. METHODS Two hundred sixty-two patients undergoing total hip replacement… 
Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients
TLDR
Enoxaparin is as safe and as effective as standard heparin in total hip replacement surgery, and two patients in the exoparine group were detected with late DVT during the postoperative period of 6 weeks.
Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement
TLDR
Prolonging enoxaparin thromboprophylaxis following hip replacement for a total of four weeks provided therapeutic benefit, by reducing the prevalence of venous thromboembolism, without compromising safety.
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.
TLDR
Low-molecular-weight heparin prophylaxis was at least as effective as oral anticoagulants, but with a marked improvement in safety, and a significantly higher benefit-risk ratio was observed for patients undergoing elective hip replacement who received extended out-of-hospital prophYLaxis.
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?
TLDR
No convincing evidence is found that starting prophylaxis preoperatively is associated with a lower incidence of venous thromboembolism than starting postoperatively, and perioperative regimens may lower the risk of postoperative thrombosis, but this positive effect is offset by an increase in postoperative major bleeding.
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
TLDR
Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxapin prophyllaxis for one week.
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
TLDR
Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxapin prophyllaxis for one week.
Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
TLDR
Inpatient programs providing treatment with either enoxaparin or adjusted-dose warfarin for a mean of 7.3 days afforded protection against venous thromboembolic disease, with overall rates of morbidity and mortality of 3.7 and 0.6 percent, respectively, and a very low rate of major bleeding complications for three months after total hip arthroplasty.
Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study.
TLDR
Extending prophylaxis with warfarin for a few more weeks beyond the hospital stay has the potential to considerably improve the outcome of patients who undergo hip arthroplasty.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.
TLDR
Prophylaxis with fixed-dose PK10169 heparin is effective and safe for patients undergoing elective hip replacement and the observed hemorrhagic rate was 4 percent in each treatment group.
Thrombosis prophylaxis with low molecular weight heparin in total hip replacement
TLDR
Per‐ and postoperative blood loss and blood transfusion requirements were significantly lower in the LMWH group, and it was not firmly established whether this benefit was also valid in the high ileofemoral region.
Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.
TLDR
Prophylaxis with enoxaparin, 40 mg once daily, is simple, safe and more effective than standard low dose unfractionated heparin in preventing deep vein thrombosis in patients undergoing elective hip replacement.
Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Clinical and economic considerations.
TLDR
Thromboprophylaxis with recommended dosages of LMWH was significantly more effective than both placebo, dextran 70 and low-dose unfractionated heparin (UH) in terms of protection against objectively diagnosed deep vein thrombosis (DVT), which is the main source of postoperative pulmonary embolism.
Prophylaxis of postoperative thromboembolism with low molecular weight heparins
TLDR
In orthopaedic surgery and general surgery, the LMWHs were superior to placebo or dextran and at least as efficient as unfractionated heparin in the prevention of deep vein thrombosis (DVT), with a trend towards a lower risk of pulmonary embolism with the former.
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
TLDR
Low molecular weight Heparin is at least as effective as unfractionated heparin in preventing deep vein thrombosis and is more effective at preventing thromBosis of the proximal veins in patients undergoing hip replacement.
Low molecular weight heparin in prevention of perioperative thrombosis.
TLDR
Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis and it remains to be shown in a suitably powered clinical trial whether low molecular weight Heparin reduces the risk of fatal pulmonary embolism compared withHeparin.
Efficacy and Cost of Low-Molecular-Weight Heparin Compared with Standard Heparin for the Prevention of Deep Vein Thrombosis after Total Hip Arthroplasty
TLDR
The approach of comparing the efficacy and cost-effectiveness of a novel drug with a standard treatment could be useful for determining the appropriate role of other innovative but often expensive new agents.
...
1
2
3
4
...